ITX

51.32

+3.95%↑

ITX

51.32

+3.95%↑

ITX

51.32

+3.95%↑

ITX

51.32

+3.95%↑

ITX

51.32

+3.95%↑

Search

Evonik Industries AG

Slēgts

SektorsCikliskās patēriņa

16.36 -2.5

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

16.36

Max

16.91

Galvenie mērījumi

By Trading Economics

Ienākumi

174M

68M

Pārdošana

12M

3.4B

P/E

Sektora vidējais

29.333

43.836

EPS

0.15

Dividenžu ienesīgums

6.09

Peļņas marža

1.998

Darbinieki

28,650

EBITDA

-39M

367M

Rekomendācijas

By TipRanks

Rekomendācijas

Neitrāls

Prognoze 12 mēnešiem

-8.31% downside

Dividendes

By Dow Jones

Dividenžu ienesīgums

Sektora vidējais

6.09%

3.27%

Nākamie ieņēmumi

2026. g. 8. maijs

Tirgus statistika

By TradingEconomics

Tirgus kapitalizācija

1.4B

7.8B

Iepriekšējā atvēršanas cena

18.86

Iepriekšējā slēgšanas cena

16.36

Ziņu noskaņojums

By Acuity

19%

81%

42 / 338 Rangs Consumer cyclical

Tehniskais rādītājs

By Trading Central

Pārliecība

Weak Bullish Evidence

Evonik Industries AG Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 31. marts 23:31 UTC

Karstas akcijas

Stocks to Watch: Nike, RH, NCino

2026. g. 31. marts 22:35 UTC

Peļņas

Nike Guides for Sales Declines Ahead as Turnaround Plan Hits Snags -- 2nd Update

2026. g. 1. apr. 00:00 UTC

Iegādes, apvienošanās, pārņemšana

The Year Is Off to the Strongest Start for Big Deals Ever -- WSJ

2026. g. 31. marts 23:50 UTC

Iegādes, apvienošanās, pārņemšana

Nxera Pharma: Partner Centessa Pharmaceuticals to Be Acquired by Lilly >LLY 4565.TO

2026. g. 31. marts 23:43 UTC

Tirgus saruna

Nikkei May Rise on Hopes for Iran War Ending Soon -- Market Talk

2026. g. 31. marts 23:33 UTC

Tirgus saruna
Galvenie ziņu notikumi

Gold Edges Higher on Signs of De-Escalating Middle East Tensions -- Market Talk

2026. g. 31. marts 23:21 UTC

Peļņas

Nike Stock Slides on Tariff Impact Despite Earnings Beat; Turnaround Continues -- Barrons.com

2026. g. 31. marts 23:14 UTC

Tirgus saruna
Peļņas

Nike CEO Says Turnaround is Taking Longer Than He'd Like -- Market Talk

2026. g. 31. marts 23:12 UTC

Tirgus saruna

Aurelia's Cash Flow Strength Highlighted by New Financing Deal -- Market Talk

2026. g. 31. marts 22:36 UTC

Peļņas

China Vanke 2025 Loss Widens >000002.SZ

2026. g. 31. marts 22:36 UTC

Peļņas

China Vanke: Increase in Inventory Impariment Provision Among Factors Weighing On Results>000002.SZ

2026. g. 31. marts 22:36 UTC

Peļņas

China Vanke 2025 Loss CNY88.56B Vs. Loss CNY49.48B >000002.SZ

2026. g. 31. marts 22:36 UTC

Peļņas

China Vanke: Will Take Time to Resolve Issues Caused by High Debt Levels>000002.SZ

2026. g. 31. marts 22:36 UTC

Peļņas

China Vanke 2025 Rev CNY233.43B Vs. CNY343.18B >000002.SZ

2026. g. 31. marts 21:46 UTC

Iegādes, apvienošanās, pārņemšana

Big Drug Companies Hunting for Deals Are Lowering Their Sights -- WSJ

2026. g. 31. marts 21:36 UTC

Tirgus saruna

West African Resources's Costs Higher Than Bull Expected -- Market Talk

2026. g. 31. marts 21:35 UTC

Peļņas

Nike Expects China Sales Down 20% in 4Q, CFO Says

2026. g. 31. marts 21:35 UTC

Peļņas

Nike Expects Modest Growth in North America, Offset by Declines in China, Converse Brand in 4Q, CFO Says

2026. g. 31. marts 21:35 UTC

Peļņas

Nike Forecasts 4Q Sales Down 2% to 4%, CFO Says

2026. g. 31. marts 21:33 UTC

Iegādes, apvienošanās, pārņemšana

Biotechs Are a Healthy Growth Bet Thanks to M&A and New Drugs -- Barrons.com

2026. g. 31. marts 21:33 UTC

Peļņas

Nike Expects Sales Down Low-Single Digits From Now Through End of Calendar Year, CFO Says

2026. g. 31. marts 21:32 UTC

Peļņas

Nike Expects 1Q to Be Final Quarter Where Tariffs Continue to Be Year-Over-Year Headwind to Margins, CFO Says

2026. g. 31. marts 21:28 UTC

Peļņas

Nike Expects to End 4Q With Elevated Inventory, CFO Says

2026. g. 31. marts 21:26 UTC

Peļņas

Nike Increasingly Confident It Will Return to Balanced Growth in North America in Direct, Wholesale Channels, CFO Says

2026. g. 31. marts 21:25 UTC

Peļņas

Nike Expects Supply-Chain Changes to Pay Off Starting in Fiscal 2027, CFO Says

2026. g. 31. marts 21:24 UTC

Tirgus saruna
Peļņas

Nike: Turnaround Plan Progressing at Different Rates -- Market Talk

2026. g. 31. marts 21:22 UTC

Peļņas

Nike CFO Expects Football Training and Basketball Will Return to Growth Over Next Few Quarters

2026. g. 31. marts 21:22 UTC

Peļņas

Nike's Sportswear Business Declined Low-Double Digits in 3Q, CFO Says

2026. g. 31. marts 21:21 UTC

Peļņas

Nike's Digital Channel Still Too Promotional, CFO Says

2026. g. 31. marts 21:20 UTC

Peļņas

Nike CEO: Converse Remains Important to Portfolio

Salīdzinājums

Cenas izmaiņa

Evonik Industries AG Prognoze

Cenas mērķis

By TipRanks

-8.31% uz leju

Prognoze 12 mēnešiem

Vidējais 15.33 EUR  -8.31%

Augstākais 20.4 EUR

Zemākais 12.2 EUR

Pamatojoties uz 12 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Evonik Industries AG — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Neitrāls

12 ratings

3

Pirkt

6

Turēt

3

Pārdot

Tehniskais rādītājs

By Trading Central

19.83 / 20Atbalsts un pretestība

Īstermiņā

Weak Bullish Evidence

Vidējā termiņā

Strong Bullish Evidence

Ilgtermiņā

Bullish Evidence

Noskaņojums

By Acuity

42 / 338 Rangs Cikliskās patēriņa

Ziņu noskaņojums

Ļoti spēcīga liecība "buļļu" tendencei

Volatilitāte

Zem vidējā

Ziņu apjoms (RCV)

Virs vidējā

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

$

Par Evonik Industries AG

Evonik Industries AG produces specialty chemicals in the Asia-Pacific, Europe, the Middle East, Africa, Central and South America, and North America. It operates through Specialty Additives, Nutrition & Care, Smart Materials, Performance Materials, and Technology & Infrastructure segments. The Specialty Additives segment provides additives for polyurethane; additives, matting agents, fumed silicas, and specialty resins for paints, coatings, and printing inks; isophorone and epoxy curing agents for coatings, adhesives, and composites; and pour-point depressants, and viscosity index improvers for coatings for oil and other lubricants for construction machinery and automotive sector. The Nutrition & Care segment offers D-/l-methionine and lysine for animal nutrition industry; amino acids and peptides; pharmaceutical active ingredients; and biocompatible and bioresorbable materials for orthopedic and medical applications; and system solutions for the cosmetics and detergent industries. The Smart Materials segment provides inorganic materials, including fumed and precipitated silicas and silanes; peroxides for paper and textile industries; specialty catalysts for synthesis and alkoxides; polymers products, such as polymide 12, polymer foam, specialty polybutadiene and polyester, alkoxides, and membranes. The Performance Materials offers C4 derivatives consisting of butadiene, MTBE, butene-1, isononanol, and DINP for use in automotive industry; and superabsorbent products for diapers and hygiene products. The Technology & Infrastructure segment provides energy management, integrated plant support and maintenance, process safety and engineering, pipelines, transport management, logistics safety, digital solutions for chemical production, and strategic site development services. The company was founded in 1873 and is headquartered in Essen, Germany.
help-icon Live chat